Memorial Sloan Kettering Cancer Center

https://www.mskcc.org/healthcare-professionals

Refer a Patient to MSKCC: mskcc.org/refer

 

ASH 2022 Conference Coverage
Avatar

ASH 2022 Initial Results From SELECT-AML-1: a Phase 2 Study of Tamibarotene + Venetoclax & Azacitidine in RARA+ Newly Diagnosed AML Patients Ineligible for Standard Induction Chemo

By ASH 2022 Conference Coverage FEATURING Eytan Stein
By ASH 2022 Conference Coverage FEATURING Eytan Stein
173 views
December 16, 2022
Comments 0
Login to view comments. Click here to Login

Featured Video

18:11
Incyte

Appropriate Management of RPED (Retinal Pigment Epithelial Detachmen…

Feat. M. Khasawneh

Featured Video

07:44
Incyte

Optimizing the Management of Patients with Polycythemia Vera (PV)

Feat. P. Bose, R. Rampal
Leukemia
18:42

Key Updates in AML, MDS, & MF From ASH

Memorial Sloan Kettering Cancer Center

A. Goldberg

330 views
15:23

SOHO 2023: Updates on the Role of SCT in ALL in the Era of CAR-T

SOHO 2023 Eleventh Annual Meeting

J. Park

90 views
13:15

SOHO 2023 Menin Inhibition for KMT2A-Rearranged ALL

SOHO 2023 Eleventh Annual Meeting

E. Stein

41 views
30:21

ASH 2022 Highlights on CML: Clinical Overview From iCMLf

International CML Foundation

M. Mauro

113 views
04:55

ASH 2022 Initial Results From SELECT-AML-1: a Phase 2 Study of Tamib…

ASH 2022 Conference Coverage

E. Stein

173 views
04:22

EHA 2022 Tamibarotene in Combination With Ven & Aza in Previously Un…

EHA 2022 Conference Coverage

E. Stein

209 views
54:58

Expert Perspectives on Treating High-Risk and R/R AML

PleXus Communications

E. Stein

142 views
04:36

Safety & Efficacy of Asciminib for Heavily Pretreated Patients With …

ecancer

M. Mauro

27 views
05:49

ASH 2021 Update on the Safety & Efficacy of Menin Inhibition in MLL-…

ASH 2021 Conference Coverage on VuMedi

E. Stein

131 views
16:42

IDH Inhibitors in Myeloid Malignancies: What Are the Mechanisms of R…

University of Miami's 2nd Biennial Miami Leukemia Symposium

E. Stein

228 views
06:19

2019 ASH Review of Frontline CLL: Is There a Role for FCR in 2020 an…

Cleveland Clinic's 20th Annual ASH Review

A. Mato

344 views
07:59

2019 ASH Review of Frontline CLL: Can We Improve CIT by Adding a Nov…

Cleveland Clinic's 20th Annual ASH Review

A. Mato

177 views
05:08

2019 ASH Review on Combinations or Sequences of Targeted Agents in C…

Cleveland Clinic's 20th Annual ASH Review

A. Mato

79 views
04:52

2019 ASH Review on Venetoclax in the R/R CLL: With Additional Follow…

Cleveland Clinic's 20th Annual ASH Review

A. Mato

32 views
08:21

2019 ASH Review on Overcoming BTKi Resistance in CLL: Era of Non-Cov…

Cleveland Clinic's 20th Annual ASH Review

A. Mato

35 views
15:19

29 y/o Male w/ CML: Allograft vs. 3rd Line Therapy - Transplant Is A…

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

M. Mauro

17 views
15:59

New Kinase Inhibitors for CML: Asciminib, PF-114, & HQP1351

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

M. Mauro

30 views
27:00

Acute Myeloid Leukemia - Overview of Available Novel Agents with Uni…

Indy Hematology Review

M. Tallman

1.8K views
07:46

Oral Abstract CML-044: Treatment-Free Remission (TFR) in Patients wi…

Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)

M. Mauro

17 views
17:58

Front-line Strategies in Ph-negative ALL

Memorial Sloan Kettering Cancer Center

M. Geyer

178 views
13:41

Updates and Challenges in the Management of Chronic Myeloid Leukemia…

Memorial Sloan Kettering Cancer Center

M. Mauro

146 views
17:13

Multi-drug Resistant and Intolerant CML: What to Do?

Memorial Sloan Kettering Cancer Center

M. Mauro

172 views
08:42

IDH Inhibitors in AML

Memorial Sloan Kettering Cancer Center

E. Stein

169 views